NEU-411
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Phase 2 · Enrolling participants
Planned enrollment: 150 participants
Study ages: 40 Years to 80 Years
Recruiting sites listed in: Israel, Italy, Poland, Spain, United Kingdom and 1 more countries/territories (see details)
No results-posting date in this record
Read trial record and resultsChecked Oct 27, 2026